ASCO GU 2023: Rucaparib Extends Survival for Metastatic, Castration-Resistant Prostate Cancer
Findings seen compared with docetaxel or second-generation androgen-receptor pathway inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.